VKTX · NASDAQ
Viking Therapeutics
Clinical-stage biotech advancing VK2735 as an oral and injectable obesity candidate.
Last updated:Jul 15, 2026Source:SEC EDGAR + company IRVerified:Reviewed against latest filingsData provider:PeptidePlanet Research
Overview
Pipeline programs
3Active trials
1Upcoming catalysts
0Indications
2ObesityMASH
AI research summary
Generated on demand from verified profile data.
The AI summarizer only sees the verified fields on this page. Every numbered citation maps to a source in the legend below.
Pipeline
Clinical trials
Upcoming catalysts
No scheduled catalysts on file for this company.
Timeline
Merged approvals, trial milestones, and catalysts. Newest first.
Dec 01, 2025 · Trial Milestone
Phase 2 · VK2735 obesity Phase 2 — primary completion (active, not recruiting)
ClinicalTrials.gov ↗Mar 26, 2024 · Trial Milestone
Viking reports Phase 1 data for oral VK2735 formulation.
Viking IR ↗Feb 27, 2024 · Trial Milestone
Viking reports VK2735 Phase 2 VENTURE obesity trial topline results.
Viking IR ↗
Verified sources
- [1]Viking IR — Viking Therapeuticsretrieved 2026-07-15
- [2]SEC EDGAR — U.S. Securities and Exchange Commissionretrieved 2026-07-15
- [3]ClinicalTrials.gov — U.S. National Library of Medicineretrieved 2026-07-15
SEC filings search: EDGAR ↗